Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Janssen Pharmaceutica discloses BARK1 inhibitors

Nov. 11, 2020

Phase III CARDINAL study of bardoxolone in Alport syndrome meets primary endpoint

Nov. 10, 2020

Phase III trial of Nefecon in primary IgAN meets key endpoints

Nov. 9, 2020

CaMK4 as potential target to slow cyst growth in PKD

Nov. 9, 2020

SYNB-8802 consumes GI oxalate in animals with acute hyperoxaluria

Nov. 6, 2020

Synlogic advances SYNB-8802 into phase I study for treatment of enteric hyperoxaluria

Nov. 5, 2020

Phase III results for molidustat in patients with renal anemia undergoing dialysis

Nov. 4, 2020

dEF-3122 improves inflammation and fibrosis in liver and kidneys of NASH mice

Nov. 3, 2020

First-in-class LDHA inhibitor CHK-336 for treating primary hyperoxaluria

Nov. 3, 2020

Dimerix announces positive data from phase II ACTION trials of DMX-200 in kidney disease

Oct. 28, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...